{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:30:00Z","timestamp":1776846600855,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["Grant Number 23K08773"],"award-info":[{"award-number":["Grant Number 23K08773"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10147-026-03005-2","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:00:00Z","timestamp":1772946000000},"page":"868-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort"],"prefix":"10.1007","volume":"31","author":[{"given":"Akira","family":"Ohtsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rogachevskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa D.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-4539","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"5","key":"3005_CR1","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70(5):404\u2013423","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3005_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"4","key":"3005_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH et al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381(4):338\u2013348","journal-title":"N Engl J Med"},{"issue":"13","key":"3005_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218\u20131230","journal-title":"N Engl J Med"},{"issue":"10","key":"3005_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"7492","key":"3005_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315\u2013322","journal-title":"Nature"},{"issue":"3","key":"3005_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3):540\u201356.e25","journal-title":"Cell"},{"issue":"1","key":"3005_CR8","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P et al (2021) An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun 12(1):2301","journal-title":"Nat Commun"},{"issue":"5","key":"3005_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM et al (2017) Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32(5):701\u201315.e7","journal-title":"Cancer Cell"},{"issue":"7","key":"3005_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.urolonc.2018.10.015","volume":"40","author":"CD Hurst","year":"2022","unstructured":"Hurst CD, Knowles MA (2022) Mutational landscape of non-muscle-invasive bladder cancer. Urol Oncol 40(7):295\u2013303","journal-title":"Urol Oncol"},{"issue":"8","key":"3005_CR11","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111(8):3110\u20133115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3005_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52915-0","volume":"15","author":"Y Loriot","year":"2024","unstructured":"Loriot Y, Kamal M, Syx L et al (2024) The genomic and transcriptomic landscape of metastastic urothelial cancer. Nat Commun 15(1):8603","journal-title":"Nat Commun"},{"issue":"1","key":"3005_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33980-9","volume":"13","author":"JS Damrauer","year":"2022","unstructured":"Damrauer JS, Beckabir W, Klomp J et al (2022) Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun 13(1):6658","journal-title":"Nat Commun"},{"issue":"10","key":"3005_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140\u20131153","journal-title":"Cancer Discov"},{"issue":"8","key":"3005_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu D, Plimack ER, Hoffman-Censits J et al (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2(8):1094\u20131096","journal-title":"JAMA Oncol"},{"issue":"1","key":"3005_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber A, Christensen E, Lamy P et al (2020) Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun 11(1):4858","journal-title":"Nat Commun"},{"issue":"1","key":"3005_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey BJ, Kelly GL, Janic A (2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25(1):104\u2013113","journal-title":"Cell Death Differ"},{"key":"3005_CR18","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.180002","author":"KJ Campbell","year":"2018","unstructured":"Campbell KJ, Tait SWG (2018) Targeting BCL-2 regulated apoptosis in cancer. Open Biol. https:\/\/doi.org\/10.1098\/rsob.180002","journal-title":"Open Biol"},{"issue":"6","key":"3005_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH et al (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23(6):703\u2013713","journal-title":"Nat Med"},{"issue":"8","key":"3005_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","unstructured":"AACR Project GENIE Consortium (2017) AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 7(8):818\u2013831","journal-title":"Cancer Discov"},{"issue":"9","key":"3005_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","volume":"12","author":"TJ Pugh","year":"2022","unstructured":"Pugh TJ, Bell JL, Bruce JP et al (2022) AACR Project GENIE: 100,000 cases and beyond. Cancer Discov 12(9):2044\u20132057","journal-title":"Cancer Discov"},{"issue":"5","key":"3005_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401\u2013404","journal-title":"Cancer Discov"},{"issue":"269","key":"3005_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):11","journal-title":"Sci Signal"},{"issue":"2","key":"3005_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J et al (2018) Oncogenic signaling pathways in the cancer genome atlas. Cell 173(2):321\u201337.e10","journal-title":"Cell"},{"issue":"7","key":"3005_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 17(7):395\u2013417","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3005_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31\u201346","journal-title":"Cancer Discov"},{"key":"3005_CR27","unstructured":"Team RC. R: A language and environment for statistical computing. Available from: https:\/\/www.R-project.org"},{"issue":"12","key":"3005_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, Chen Z, Wise H et al (2022) Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep 41(12):111859","journal-title":"Cell Rep"},{"issue":"113368","key":"3005_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113368","volume":"195","author":"C Helal","year":"2023","unstructured":"Helal C, Pobel C, Bayle A et al (2023) Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur J Cancer 195(113368):113368","journal-title":"Eur J Cancer"},{"issue":"100271","key":"3005_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100271","volume":"6","author":"E Jia","year":"2024","unstructured":"Jia E, Agarwal G (2024) Clinical utility of liquid biopsy in bladder cancer: the beginning of a new era. J Liq Biopsy 6(100271):100271","journal-title":"J Liq Biopsy"},{"key":"3005_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.euros.2025.03.009","volume":"75","author":"BJ Guercio","year":"2025","unstructured":"Guercio BJ, Whiting K, Shah RH et al (2025) Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance). Eur Urol Open Sci 75:80\u201388","journal-title":"Eur Urol Open Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03005-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:34:43Z","timestamp":1776843283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03005-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03005-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This study used only de-identified, publicly available data and did not involve direct interaction with human participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}